O C Freedman1, G G Fletcher2, S Gandhi3, M Mates4, S F Dent5, M E Trudeau1, A Eisen1. 1. Durham Regional Cancer Centre, Oshawa, ON. 2. Program in Evidence-Based Care, Cancer Care Ontario; and Department of Oncology, McMaster University, Hamilton, ON. 3. Sunnybrook Health Science Centre, Toronto, ON. 4. Cancer Centre of Southeastern Ontario, Kinston General Hospital, and Queen's University, Kingston, ON. 5. The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON.
Abstract
BACKGROUND: Cancer Care Ontario's Program in Evidence-Based Care (pebc) recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic review to answer the question "What is the optimal systemic therapy for patients with early-stage, operable breast cancer, when patient and disease factors are considered?" The question was addressed in three parts: cytotoxic chemotherapy, endocrine treatment, and her2 (human epidermal growth factor receptor 2)-targeted therapy. METHODS: For the systematic review, the literature in the medline and embase databases was searched for the period January 2008 to May 2014. The Standards and Guidelines Evidence directory of cancer guidelines and the Web sites of major oncology guideline organizations were also searched. The basic search terms were "breast cancer" and "systemic therapy" (chemotherapy, endocrine therapy, targeted agents, ovarian suppression), and results were limited to randomized controlled trials (rcts), guidelines, systematic reviews, and meta-analyses. RESULTS: Several hundred documents that met the inclusion criteria were retrieved. Meta-analyses from the Early Breast Cancer Trialists' Collaborative Group encompassed many of the rcts found. Several additional studies that met the inclusion criteria were retained, as were other guidelines and systematic reviews. SUMMARY: The results of the systematic review constitute a comprehensive compilation of high-level evidence, which was the basis for the 2014 pebc guideline on systemic therapy for early breast cancer. The review of the evidence for systemic endocrine therapy (adjuvant tamoxifen, aromatase inhibitors, and ovarian ablation and suppression) is presented here; the evidence for chemotherapy and her2-targeted treatment-and the final clinical practice recommendations-are presented separately in this supplement.
BACKGROUND:Cancer Care Ontario's Program in Evidence-Based Care (pebc) recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic review to answer the question "What is the optimal systemic therapy for patients with early-stage, operable breast cancer, when patient and disease factors are considered?" The question was addressed in three parts: cytotoxic chemotherapy, endocrine treatment, and her2 (humanepidermal growth factor receptor 2)-targeted therapy. METHODS: For the systematic review, the literature in the medline and embase databases was searched for the period January 2008 to May 2014. The Standards and Guidelines Evidence directory of cancer guidelines and the Web sites of major oncology guideline organizations were also searched. The basic search terms were "breast cancer" and "systemic therapy" (chemotherapy, endocrine therapy, targeted agents, ovarian suppression), and results were limited to randomized controlled trials (rcts), guidelines, systematic reviews, and meta-analyses. RESULTS: Several hundred documents that met the inclusion criteria were retrieved. Meta-analyses from the Early Breast Cancer Trialists' Collaborative Group encompassed many of the rcts found. Several additional studies that met the inclusion criteria were retained, as were other guidelines and systematic reviews. SUMMARY: The results of the systematic review constitute a comprehensive compilation of high-level evidence, which was the basis for the 2014 pebc guideline on systemic therapy for early breast cancer. The review of the evidence for systemic endocrine therapy (adjuvant tamoxifen, aromatase inhibitors, and ovarian ablation and suppression) is presented here; the evidence for chemotherapy and her2-targeted treatment-and the final clinical practice recommendations-are presented separately in this supplement.
Entities:
Keywords:
Early breast cancer; aromatase inhibitors; endocrine therapy; hormonal therapy; hormone receptor–positive breast cancer; ovarian ablation; ovarian suppression; tamoxifen
Authors: Nancy E Davidson; Anne M O'Neill; Allen M Vukov; C Kent Osborne; Silvana Martino; Douglas R White; Martin D Abeloff Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: C Markopoulos; M Chrissochou; A Michailidou; E Tzoracoleftherakis; G Xepapadakis; J Papadiamantis; J Misitzis; V Zobolas; D Bafaloukos; H Gogas Journal: Anticancer Drugs Date: 2005-09 Impact factor: 2.248
Authors: Asgerdur Sverrisdottir; Hemming Johansson; Ulla Johansson; Jonas Bergh; Samuel Rotstein; Larserik Rutqvist; Tommy Fornander Journal: Breast Cancer Res Treat Date: 2011-05-29 Impact factor: 4.872
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Emanuela Rossi; Alessandro Morabito; Ermelinda De Maio; Francesca Di Rella; Giuseppe Esposito; Adriano Gravina; Vincenzo Labonia; Gabriella Landi; Francesco Nuzzo; Carmen Pacilio; Maria Carmela Piccirillo; Giuseppe D'Aiuto; Massimiliano D'Aiuto; Massimo Rinaldo; Gerardo Botti; Ciro Gallo; Francesco Perrone; Andrea de Matteis Journal: J Clin Oncol Date: 2007-12-17 Impact factor: 44.544
Authors: Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes Journal: Lancet Oncol Date: 2010-11-17 Impact factor: 41.316
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Allan Hackshaw; Michael Baum; Tommy Fornander; Bo Nordenskjold; Antonio Nicolucci; Kathryn Monson; Sharon Forsyth; Krystyna Reczko; Ulla Johansson; Helena Fohlin; Miriam Valentini; Richard Sainsbury Journal: J Natl Cancer Inst Date: 2009-02-24 Impact factor: 13.506
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: T Reimer; A Stachs; V Nekljudova; S Loibl; S Hartmann; K Wolter; G Hildebrandt; B Gerber Journal: Geburtshilfe Frauenheilkd Date: 2017-02 Impact factor: 2.915
Authors: Elke Peters; Tobias Anzeneder; Christian Jackisch; Thomas Dimpfl; Georg Kunz; Alexander Katalinic; Annika Waldmann Journal: Dtsch Arztebl Int Date: 2015-08-31 Impact factor: 5.594
Authors: Joanne Kotsopoulos; Tomasz Huzarski; Jacek Gronwald; Christian F Singer; Pal Moller; Henry T Lynch; Susan Armel; Beth Karlan; William D Foulkes; Susan L Neuhausen; Leigha Senter; Nadine Tung; Jeffrey N Weitzel; Andrea Eisen; Kelly Metcalfe; Charis Eng; Tuya Pal; Gareth Evans; Ping Sun; Jan Lubinski; Steven A Narod Journal: J Natl Cancer Inst Date: 2016-09-06 Impact factor: 13.506
Authors: Milena Rondón-Lagos; Victoria E Villegas; Nelson Rangel; Magda Carolina Sánchez; Peter G Zaphiropoulos Journal: Int J Mol Sci Date: 2016-08-19 Impact factor: 5.923